GlassScriptPhysician profile
Tessa Weigel
NPI 1073995353
$5,412.67
in general payments reported to CMS, 2019-2025
21 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $799 · 2022: $1,146 · 2023: $1,165 · 2024: $1,041 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,468.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,000.27 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $662.02 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $563.72 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $514.96 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $511.26 | 2021-2025 | Rayaldee |
| Amgen INC. | $503.85 | 2021-2024 | Parsabiv, Tavneos, Aranesp |
| Akebia Therapeutics INC | $351.54 | 2021-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $219.22 | 2021-2024 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $205.84 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $187.18 | 2021-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $112.40 | 2021-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.86 | 2023-2024 | Jardiance |
| Daiichi Sankyo INC. | $94.10 | 2022-2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $82.15 | 2021-2025 | Jynarque |
| Ardelyx, INC. | $67.92 | 2024-2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63.09 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $54.48 | 2021 | |
| Mallinckrodt Hospital Products INC. | $51.62 | 2021-2024 | Acthar |
| Abbvie INC. | $23.87 | 2021 | |
| Ani Pharmaceuticals, INC. | $18.36 | 2022 | |
| Genzyme Corporation | $16.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tessa Weigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.